EUVIMEDEUVIMED entdecken
Crossref

Identification of Dual Super-Response in Patients With Asthma and CRSwNP Treated With Mepolizumab

Miguel Estravís, David Carreiras-Quintas, Juan C Triviño, Jacqueline Pérez-Pazos, María Gil-Melcón, Asunción García-Sánchez, Jacinto Ramos, Manuel Gómez-García, Emma Moreno-Jimenez, Natalia Morgado, Cristina Martín-García, Francisco J Muñoz-Bellido und 4 weitere

Journal of Investigational Allergology and Clinical Immunology · 2026

DOI: 10.18176/jiaci.1102 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Investigational Allergology and Clinical Immunology, 2026. Verfasst von Miguel Estravís und 15 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain. Hauptthemen laut MEDLINE: Asthma, Antibodies, Monoclonal, Humanized, Nasal Polyps, Sinusitis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) are both type 2 (T2) inflammatory diseases that frequently co-occur and are interconnected through shared immunological pathways. The anti–IL-5 monoclonal antibody mepolizumab has shown efficacy in reducing eosinophilic inflammation and improving clinical outcomes. However, the molecular mechanisms underlying response to treatment, particularly at the transcriptomic level, remain underexplored. We aimed to investigate peripheral blood transcriptomic changes and identify potential biomarkers associated with dual super-response to mepolizumab in patients with severe asthma and CRSwNP.

Methods

The study population comprised 29 participants (19 patients with severe asthma and CRSwNP and 10 healthy controls). Whole blood RNA sequencing was performed before and after treatment with mepolizumab in 6 patients, followed by validation of candidate genes using qPCR. Clinical responses were assessed using the FEOS score (FEV1, exacerbations, oral corticosteroids, symptoms) and lung function measurements, and the 22-item Sino-Nasal Outcome Test (SNOT-22) score.

Results

Mepolizumab significantly improved clinical parameters, including exacerbation rates, asthma control, and the SNOT-22 score. Transcriptomic analysis identified 156 differentially expressed genes after treatment with mepolizumab, significantly enriching immune and inflammatory pathways. Twelve candidate genes were studied. Three of these genes (PNPLA1, C3AR1, and RGS1) were validated as potential predictors of super-response to treatment of asthma and CRSwNP. Baseline expression levels of RGS1 were associated with dual super-response in asthma and CRSwNP.

Conclusion

This study provides new insights into transcriptomic changes following mepolizumab treatment and highlights RGS1 as a potential biomarker for predicting dual super-response in asthma and CRSwNP. Our findings contribute to precision medicine approaches and support the identification of optimal candidates for anti–IL-5 therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaAntibodies, Monoclonal, HumanizedNasal PolypsSinusitisRhinitisAnti-Asthmatic AgentsHumansFemaleMaleMiddle AgedAdultTranscriptomeChronic DiseaseBiomarkersTreatment OutcomeGene Expression ProfilingAgedInterleukin-5

Stichwörter der Autor:innen

CRSwNPDual super-responseMepolizumabPrecision medicineResponse to treatmentSevere asthmaWhole blood transcriptome

Substanzen

mepolizumabAntibodies, Monoclonal, HumanizedAnti-Asthmatic AgentsBiomarkersInterleukin-5

Autor:innen und Institutionen

  • Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain.
  • Universidad de Salamanca, Microbiology and Genetics Department, Salamanca, Spain.
  • Instituto de Salud Carlos III, Red de Enfermedades Inflamatorias - RICORS, Madrid, Spain.
  • Universidad de Salamanca, Salamanca, Spain.
  • Sistemas Genómicos SL, Synlab Group, Paterna, Spain.
  • Hospital Universitario de Salamanca, Pharmacogenetics and Precision Medicine Unit, Clinical Biochemistry Department, Salamanca, Spain.

Zitieren

APA

Estravís, M., Carreiras-Quintas, D., Triviño, J. C., Pérez-Pazos, J., Gil-Melcón, M., García-Sánchez, A., Ramos, J., Gómez-García, M., Moreno-Jimenez, E., Morgado, N., Martín-García, C., Muñoz-Bellido, F. J., Curto, E., Sanz, C., Isidoro-García, M., & Dávila, I. (2026). Identification of Dual Super-Response in Patients With Asthma and CRSwNP Treated With Mepolizumab. Journal of Investigational Allergology and Clinical Immunology. https://doi.org/10.18176/jiaci.1102

Vancouver

Estravís M, Carreiras-Quintas D, Triviño JC, Pérez-Pazos J, Gil-Melcón M, García-Sánchez A, et al. Identification of Dual Super-Response in Patients With Asthma and CRSwNP Treated With Mepolizumab. Journal of Investigational Allergology and Clinical Immunology. 2026. doi:10.18176/jiaci.1102

BibTeX
@article{Estravs2026,
  author = {Estravís, Miguel and Carreiras-Quintas, David and Triviño, Juan C and Pérez-Pazos, Jacqueline and Gil-Melcón, María and García-Sánchez, Asunción and Ramos, Jacinto and Gómez-García, Manuel and Moreno-Jimenez, Emma and Morgado, Natalia and Martín-García, Cristina and Muñoz-Bellido, Francisco J and Curto, Elena and Sanz, Catalina and Isidoro-García, María and Dávila, Ignacio},
  title = {Identification of Dual Super-Response in Patients With Asthma and CRSwNP Treated With Mepolizumab},
  journal = {Journal of Investigational Allergology and Clinical Immunology},
  year = {2026},
  doi = {10.18176/jiaci.1102}
}
Kostenlos starten →